NVO•benzinga•
BMO Capital Downgrades Novo Nordisk to Market Perform, Lowers Price Target to $64
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 17, 2025 by benzinga